Unique ID issued by UMIN | UMIN000055039 |
---|---|
Receipt number | R000062878 |
Scientific Title | Investigation of whether the Glasgow Prognostic Score is a predictor of response to nivolumab in combination with low-dose ipilimumab as first-line therapy in patients with advanced gastric or esophagogastric junction cancer with MSI-H(WJOG18624G) |
Date of disclosure of the study information | 2024/07/22 |
Last modified on | 2024/07/22 11:54:39 |
Investigation of whether the Glasgow Prognostic Score is a predictor of response to nivolumab in combination with low-dose ipilimumab as first-line therapy in patients with advanced gastric or esophagogastric junction cancer with MSI-H(WJOG18624G)
CPS evaluation in NO LIMIT study
Investigation of whether the Glasgow Prognostic Score is a predictor of response to nivolumab in combination with low-dose ipilimumab as first-line therapy in patients with advanced gastric or esophagogastric junction cancer with MSI-H(WJOG18624G)
GPS evaluation in NO LIMIT study
Japan |
Advanced gastric or oesophagogastric junction cancer with MSI-H
Gastroenterology | Hematology and clinical oncology |
Others
NO
To collect C-reactive protein (CRP) values at screening and calculate the Glasgow Prognostic Score in patients with advanced gastric or oesophagogastric junction cancer with MSI-H who participated in the NO LIMIT study.
Others
To collect C-reactive protein (CRP) values at screening and calculate the Glasgow Prognostic Score in patients with advanced gastric or oesophagogastric junction cancer with MSI-H who participated in the NO LIMIT study.
To collect CRP values at screening in patients with advanced gastric or oesophagogastric junction cancer with MSI-H who participated in the WJOG13320G/CA209-7W7 (hereafter NO LIMIT) study and calculate the Glasgow Prognostic Score
Observational
Not applicable |
Not applicable |
Male and Female
1) Enrolled in the NO LIMIT trial and treated with NIVO+IPI
None
29
1st name | Hisato |
Middle name | |
Last name | Kawakami |
Kindai University Faculty of Medicine
Department of Medical Oncology
589-8511
377-2 Ohno-higashi, Osaka-Sayama, Osaka
072-366-0221
kawakami_h@med.kindai.ac.jp
1st name | Naoki |
Middle name | |
Last name | Ishizuka |
West Japan Oncology Group
WJOG datacenter
556-0016
Namba Plaza Bldg. 304-1-5-7, Motomachi Naniwa-ku, Osaka 556-0016 JAPAN
06-6633-7400
datacenter@wjog.jp
West Japan Oncology Group
None
Self funding
Ethics Committee, Faculty of Medicine, Kinki University
377-2 Ohno-Higashi, Osaka-Sayama, Osaka
072-366-0221
zizen@med.kindai.ac.jp
NO
2024 | Year | 07 | Month | 22 | Day |
Unpublished
Preinitiation
2024 | Year | 04 | Month | 30 | Day |
2024 | Year | 09 | Month | 01 | Day |
2025 | Year | 03 | Month | 01 | Day |
To collect C-reactive protein (CRP) values at screening in patients with advanced gastric or oesophagogastric junction cancer with MSI-H in the NO LIMIT study and calculate the Glasgow Prognostic Score to assess its usefulness in predicting treatment response (WJOG18624G) for nivolumab in combination with low-dose ipilimumab To investigate the usefulness of nivolumab plus low-dose ipilimumab in predicting treatment response (WJOG18624G)
2024 | Year | 07 | Month | 22 | Day |
2024 | Year | 07 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000062878
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |